Physician profile
Morgan Dewitt
NPI 1538882444
$984.50
in general payments reported to CMS, 2019-2025
12 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $221 · 2024: $369 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $353.77 | 2023-2025 | Sublocade |
| Braeburn INC. | $235.44 | 2024-2025 | Brixadi |
| Supernus Pharmaceuticals, INC. | $138.47 | 2024 | Qelbree |
| Orexo US, INC. | $50.01 | 2023-2024 | Zubsolv |
| Neurocrine Biosciences, INC. | $38.40 | 2023-2024 | Ingrezza |
| Corium, LLC | $29.94 | 2023-2024 | Azstarys |
| Alkermes, INC. | $24.08 | 2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $23.92 | 2023 | Spravato |
| Axsome Therapeutics, INC. | $23.85 | 2023 | Auvelity |
| Sage Therapeutics, LLC | $23.20 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $22.49 | 2023 | Austedo Xr |
| Abbvie INC. | $20.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.